A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam

Brain and Development

Volumn 26, Issue 8, 2004, Pages 530-534

  Kosaki, Kenjiro ^a   Tamura, Kazuyo ^a   Sato, Reiko ^a   Samejima, Hazuki ^a   Tanigawara, Yusuke ^a   Takahashi, Takao ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Benzodiazepine; Clobazam; CYP; P450; Pharmacogenetics; Poor metabolizer

Indexed keywords

NORCLOBAZAM;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYP2C19 GENE; EPILEPSY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; STEADY STATE; WILD TYPE;

ADOLESCENT; ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; INFANT; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 7744226277     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2004.02.010     Document Type: Article

References (23)

1. Bun H., Coassolo P., Gouezo F., Serrandimigni A., Cano J.P. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 24:1986;287-293
2. Shorvon S.D. Benzodiazepines: clobazam. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic drugs. 1995;763-777 Raven Press, New York
3. Nakamura F., Suzuki S., Nishimura S., Yagi K., Seino M. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia. 37:1996;728-735
4. Bun H., Monjanel-Mouterde S., Noel F., Durand A., Cano J.P. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxcol. 67:1990;136-140
5. Sennoune S., Mesdjian E., Bonneton J., Genton P., Dravet C., Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit. 14:1992;269-274
6. Contin M., Riva R., Albani F., Baruzzi A.A. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 21:1999;604-608
7. Riva R., Albani F., Contin M., Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet. 31:1996;470-493
8. Goldstein J.A., Faletto M.B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J.L., et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 33:1994;1743-1752
9. Andersson T., Regardh C.G., Dahl-Puustinen M.L., Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit. 12:1990;415-416
10. Contin M., Sangiorgi S., Riva R., Parmeggiani A., Albani F., Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit. 24:2002;737-741
11. Parmeggiani A., Posar A., Sangiorgi S., Giovanardi-Rossi P. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain Dev. 26:2003;63-66
12. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 52:2001;349-355
13. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 181-182:2002;447-452
14. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 269:1994;15419-15422
15. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 46:1994;594-598
16. Drouet-Coassolo C., Aubert C., Coassolo P., Cano J.P. Capillary gas chromatographic-mass spectrometric method for the identification and quantification of some benzodiazepines and their unconjugated metabolites in plasma. J Chromatogr. 487:1989;295-311
17. Itoh K., Inoue K., Nakao H., Yanagiwara S., Tada H., Suzuki T. Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population. Anal Biochem. 284:2000;160-162
18. Kosaki K., Suzuki T., Muroya K., Hasegawa T., Sato S., Matsuo N., et al. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab. 87:2002;3529-3533
19. Fielding S., Hoffman I. Pharmacology of antianxiolytic drugs with special reference to clobazam. Br J Clin Pharmacol. 7:(Supplement):1979;7-15
20. Haigh J.R., Pullar T., Gent J.P., Dailley C., Feely M. N-desmethyl-clobazam: a possible alternative to clobazam in the treatment of refractory epilepsy. Br J Clin Pharmacol. 23:1987;213-218
21. Furuta T., Ohashi K., Kamata T., Takashima M., Kosuge K., Kawasaki T., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 129:1998;1027-1030
22. Mamiya K., Hadama A., Yukawa E., Ieiri I., Otsubo K., Ninomiya H., et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 55:2000;821-825
23. Blaisdell J., Mohrenweiser H., Jackson J., Ferguson S., Coulter S., Chanas B., et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 12:2002;703-711